Overview and Lineup: Xi, SP, and da Vinci 5
The da Vinci is Intuitive Surgical's multi-arm, surgeon-controlled robotic platform for minimally invasive soft-tissue surgery. Three systems are currently sold: the da Vinci Xi (launched 2014), the da Vinci SP for single-port access (FDA-cleared 2018), and the da Vinci 5 (cleared 2024).
Intuitive reports an installed base of roughly 9,900+ da Vinci systems worldwide as of year-end 2024, per Intuitive Surgical investor filings. The Xi is the workhorse across general, urologic, gynecologic, and thoracic procedures; the SP is aimed at transoral, urologic, and colorectal work through a single 2.5 cm cannula; da Vinci 5 adds Force Feedback instruments and a redesigned computing stack.
The system is not autonomous. The surgeon sits at an immersive console and drives the instruments; the patient-side cart holds the arms. Nothing on the platform moves without a surgeon input, and Intuitive markets it as a tele-manipulator, not a decision-making system.
| System | FDA cleared | Ports | Notable capability | Primary use |
|---|---|---|---|---|
| da Vinci Xi | 2014 | 4 arms, multi-port | Overhead boom, extended reach across quadrants | General, urology, gynecology, thoracic |
| da Vinci SP | 2018 | 1 arm, 3 instruments + camera through single cannula | Single-port access through 2.5 cm incision | Transoral, urology, select colorectal |
| da Vinci 5 | 2024 | 4 arms, multi-port | Force Feedback instruments, new computing stack | Successor to Xi in staged US rollout |
Specs and Instruments
Da Vinci Xi uses 8 mm EndoWrist instruments (5 mm for select tools) with seven degrees of freedom at the wrist, plus grip. Intuitive publishes the current instrument catalog in the da Vinci instruments library, covering graspers, needle drivers, monopolar and bipolar energy, vessel sealers, and staplers.
The Firefly fluorescence imaging system injects an indocyanine green (ICG) channel into the endoscope, letting the surgeon toggle near-infrared visualization of perfusion, bile ducts, and ureters intra-operatively. The endoscope is a 3D HD stereo camera, and the surgeon views a stereoscopic image at the console.
Instruments are lifed: each has a fixed number of uses tracked by the system, after which it will not actuate. This per-use consumable model — rather than the capital price of the cart — is the primary revenue line, and it is worth modeling before signing.
| Component | Spec |
|---|---|
| Instrument diameter (Xi) | 8 mm standard, 5 mm select |
| Instrument articulation | EndoWrist, 7 DOF + grip |
| Endoscope | 3D HD stereoscopic, 8 mm or 12 mm |
| Fluorescence | Firefly ICG near-infrared imaging |
| Console | Immersive stereo viewer, foot pedals, master controllers |
| Arms | 4 arms on overhead boom (Xi), single arm (SP) |
| Instrument life | Fixed use count, tracked per-instrument |
| Trained procedures | Prostatectomy, hysterectomy, colorectal resection, hernia repair, cholecystectomy, others |
Approved Procedures and Where the Evidence Is Strongest
The da Vinci has 510(k) clearances across general laparoscopic, urologic, gynecologic, thoracoscopic, and transoral surgery. In practice the highest-volume procedures are radical prostatectomy, hysterectomy, inguinal and ventral hernia repair, colorectal resection, and cholecystectomy.
The evidence is strongest — and least controversial — for radical prostatectomy, where robot-assisted approaches dominate US practice. For hysterectomy and general surgery the comparison is against a mature laparoscopic baseline; JAMA (Sheetz et al., 2020) found robotic use for common general surgery procedures grew from 1.8% to 15.1% between 2012 and 2018 without a corresponding reduction in complication rates versus laparoscopy.
The honest read: da Vinci consistently delivers laparoscopic-equivalent outcomes with a different ergonomic and training profile, and clear wins in specific anatomy (deep pelvis, single-port transoral). It is not a shortcut around surgical judgment.
- Radical prostatectomy — dominant use case, deep pelvic anatomy favors wristed instruments.
- Hysterectomy — high volume, outcome parity with laparoscopy in most series.
- Inguinal and ventral hernia repair — growing volume, cost-sensitive comparison to open and lap.
- Colorectal resection — low anterior resection and right colectomy the most common.
- Cholecystectomy — increasingly done robotically, though clinical benefit vs laparoscopy is contested.
- Transoral (SP) — oropharyngeal resection through the mouth, no external incision.
Cost and Hospital Adoption
System list price is commonly cited in the $1.5M–$2.5M range for a Xi, with da Vinci 5 higher; annual service contracts run into six figures. The larger recurring line is EndoWrist instrument and accessory consumption, which Intuitive discloses as Instruments & Accessories revenue in its 10-K.
Intuitive's annual reports show worldwide da Vinci procedures growing double digits year over year, with more than 2.6 million procedures performed in 2024. Instruments & Accessories is now the majority of company revenue — the razor-and-blades model in practice.
For a hospital, the question is rarely whether the robot works — it does — but whether the case mix supports the utilization needed to amortize capital and per-procedure cost. A system idling below one case per day is a financial problem regardless of how well it operates.
Surgeon Learning Curve and Training
Intuitive runs a structured training pathway — online modules, simulator time on the da Vinci Skills Simulator, hands-on courses, and case observation — before a surgeon is credentialed on a system. Hospital credentialing committees set the number of proctored cases required.
Published learning-curve estimates vary by procedure and by how proficiency is defined. For radical prostatectomy, older series put the operative-time curve at roughly 20–40 cases and the oncologic-outcome curve considerably longer; hernia and cholecystectomy plateau faster. New robotic surgeons underperform their own open or laparoscopic baseline during the curve — this is expected and is why proctoring exists.
The console removes tremor, restores wrist articulation lost in straight-stick laparoscopy, and eliminates the fulcrum effect at the port — but it also removes haptic feedback (partially restored on da Vinci 5's Force Feedback instruments). Surgeons compensate with visual cues, which is itself a trained skill.
Alternatives: Versius, Hugo, and Rosa
The competitive set for soft-tissue robotic surgery is narrower than the marketing suggests. CMR Surgical's Versius uses modular, cart-based arms and is deployed across the UK NHS, Europe, and select US sites. Medtronic's Hugo RAS is also modular, with a growing OUS footprint and staged US clearances. Stryker's Mako and Zimmer Biomet's Rosa are orthopedic — knee and hip — not soft-tissue peers, and it is worth being precise about that distinction in vendor conversations.
The honest comparison for a hospital evaluating a first robotic soft-tissue platform: da Vinci wins on installed base, instrument catalog depth, and surgeon familiarity; Versius and Hugo compete on modular footprint, per-case economics, and lower entry cost. Ortho robots solve a different problem and belong on a separate evaluation.
- da Vinci Xi / 5 — largest install base, deepest EndoWrist catalog, Firefly ICG.
- da Vinci SP — the only widely-cleared single-port robotic platform.
- CMR Versius — modular arms, strong OUS presence, growing US clearances.
- Medtronic Hugo RAS — modular, per-procedure economics pitch, staged US rollout.
- Mako / Rosa — orthopedic (knee, hip), not a soft-tissue alternative.
Bottom Line
The da Vinci Xi remains the default soft-tissue surgical robot in 2026, with the SP owning single-port work and da Vinci 5 taking over the multi-port line. Outcomes are broadly equivalent to laparoscopy across most procedures, with clear ergonomic and anatomic wins in specific cases. The buying decision is about utilization, consumables, and surgeon pipeline — not about whether the robot works.
Model instrument-consumable spend and case volume per surgeon before comparing capital price across da Vinci, Versius, and Hugo.
FAQs
How many da Vinci systems are installed worldwide?
Intuitive Surgical reported an installed base of roughly 9,900+ da Vinci systems worldwide as of year-end 2024, with more than 2.6 million procedures performed in 2024.
What procedures is the da Vinci Xi cleared for?
The Xi has 510(k) clearance across general laparoscopic, urologic, gynecologic, thoracoscopic, and select transoral procedures. The highest-volume real-world uses are radical prostatectomy, hysterectomy, hernia repair, colorectal resection, and cholecystectomy.
How does da Vinci differ from da Vinci 5?
Da Vinci 5, cleared by the FDA in 2024, adds Force Feedback instruments that partially restore haptic sensation, a new computing stack, and updated ergonomics. It is a staged successor to the Xi rather than a replacement of the SP.
What are the real alternatives to the da Vinci for soft-tissue surgery?
CMR Surgical's Versius and Medtronic's Hugo RAS are the two active soft-tissue competitors, both modular and cart-based. Stryker's Mako and Zimmer Biomet's Rosa are orthopedic platforms and do not compete for the same cases.
How long is the surgeon learning curve on da Vinci?
It varies by procedure. Operative-time proficiency for radical prostatectomy is commonly reported at roughly 20–40 cases; oncologic-outcome parity takes considerably longer. Hernia and cholecystectomy plateau faster. Hospital credentialing committees set the proctored case count.